Body Fat Distribution and Body Composition During GnRH Agonist Therapy

Yamasaki, Hideki; Douchi, Tsutomu; Yamamoto, Shinako; Oki, Toshimichi; Kuwahata, Riki; Nagata, Yukihiro

doi:10.1097/00006250-200103000-00003

Cited by 18 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12/16 However, change in body fat distribution is not mediated by a single factor but rather by several factors. 11 In this study we found that an increased percentage of trunk fat mass undergoes a greater aging effect. The percentage of leg fat mass did not change with aging.…”

Section: Discussionmentioning

confidence: 56%

See 1 more Smart Citation

Difference in segmental lean and fat mass components between pre- and postmenopausal women

Douchi¹,

Yonehara²,

Kawamura³

et al. 2007

Menopause

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 56%

“…11 In fact, the shift toward upper body fat distribution after menopause has been explained by the shift toward a hypoestrogenic environment. 12/16 However, change in body fat distribution is not mediated by a single factor but rather by several factors.…”

Section: Discussionmentioning

confidence: 99%

Difference in segmental lean and fat mass components between pre- and postmenopausal women

Douchi¹,

Yonehara²,

Kawamura³

et al. 2007

Menopause

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies indicated that therapy with GnRH agonists modifies the body composition with the FM being the main affected component and slight reductions in the FFM (20,(34)(35)(36). However, these therapies were performed to treat specific pathophysiological conditions with no dietary control.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, a recent study report that GnRH may have different roles outside the hypothalamus-pituitary-reproductive axis (34).…”

Section: Discussionmentioning

confidence: 99%

Changes in body composition and mRNA expression of ghrelin and lipoprotein lipase in rats treated with leuprolide acetate, a GnRH agonist

et al. 2017

View full text Add to dashboard Cite

Abstract. Leuprolide acetate (LA), a gonadotropin-releasing hormone (GnRH) agonist, was identified to cause changes in body weight in experimental and clinical trials; however, to date, the effect of LA on the body composition has not been properly assessed. The aim of the present study was to evaluate the long-term effect of LA administration on body composition and the mRNA expression of ghrelin and lipoprotein lipase (LPL) in rats. Ovariectomized (OVX), ovariectomized and LA-treated (OVX+LA), non-ovariectomized (CTRL) and non-ovariectomized but LA-treated (LA) rats were used. LA treatment was performed by intramuscular injection at 5 µg/kg every 72 h over 120 days. Analysis of body composition and mRNA expression of ghrelin and lipoprotein lipase were performed. The results indicated significant changes in body composition after treatment; in the OVX, LA, OVX+LA and CTRL group, the body weight was increased by 216.1, 183.7, 175.4 and 150.1%, respectively, compared with baseline. The fat mass in the LA group was 14% higher than that in the CTRL group, while that in the OVX group was 19% higher than that in the OVX+LA, and the fat-free mass was similar between the LA and CTRL as well as the OVX and OVX+LA groups. Following 120 days of treatment, the mRNA expression of ghrelin and LPL in the LA group was ~20% higher than that in the CTRL group, while that in the OVX+LA was downregulated in comparison with that in the OVX group. The results of the present study confirmed changes in body composition and mRNA expression of ghrelin and LPL caused by long-term administration of LA. LA may contribute to regulate food consumption and exert control over adipogenesis.

show abstract

“…Menopause-related shift Table 1. Baseline characteristics, anthropometric variables, and serum androgen levels in women with PCOS (n=67) toward upper body fat distribution has mainly been explained by estrogen deficiency [12][13][14] because estrogens influence gluteofemoral adiposity, as evidenced by preferential gluteofemoral fat deposit with the pubertal onset of ovarian function [15,16]. Lipoprotein lipase activity in reproductive-aged women is greater in gluteofemoral adipose tissue than in abdominal adipose tissue [15,16].…”

Section: Discussionmentioning

confidence: 99%

Relationships among Serum Testosterone Levels, Body Fat and Muscle Mass Distribution in Women with Polycystic Ovary Syndrome.

2001

Self Cite

View full text Add to dashboard Cite

Abstract.We investigated the relationships among serum testosterone levels, body fat and muscle mass distribution in women with polycystic ovary syndrome (PCOS).Subjects were 67 women with PCOS (mean age±standard deviation, 28.8±6.6 years). Baseline characteristics included age and height. Trunk-leg fat ratio and trunk-leg muscle ratio were assessed with dual-energy x-ray absorptiometry.Serum testosterone and dehydroepiandrosterone sulfate levels were measured with radioimmunoassays. Relationships among serum testosterone levels, body fat and muscle mass distribution were investigated using Pearson and partial correlation tests. Serum testosterone levels were positively correlated with trunk-leg fat ratio (r=0.398, P<0.01), but were inversely correlated with trunk-leg muscle ratio (r= -0.332, P<0.05).Trunk-leg muscle ratio was inversely correlated with trunk-leg fat ratio (r= -0.360, P<0.01).Serum testosterone levels were still correlated with trunk-leg fat ratio (r=0.500, P<0.001) and trunk-leg muscle ratio (r= -0.286, P <0.05), after adjusting for age and height. Trunk-leg fat ratio was still correlated with trunk-leg muscle ratio, after adjusting for age, height, and serum testosterone levels. Based on these results, we concluded that higher serum testosterone levels may contribute to the upper body fat distribution and peripheral muscle mass distribution.In addition, peripheral muscle mass distribution may also contribute to the upper body fat distribution.

show abstract

Body Fat Distribution and Body Composition During GnRH Agonist Therapy

Cited by 18 publications

References 15 publications

Difference in segmental lean and fat mass components between pre- and postmenopausal women

Difference in segmental lean and fat mass components between pre- and postmenopausal women

Changes in body composition and mRNA expression of ghrelin and lipoprotein lipase in rats treated with leuprolide acetate, a GnRH agonist

Relationships among Serum Testosterone Levels, Body Fat and Muscle Mass Distribution in Women with Polycystic Ovary Syndrome.

Contact Info

Product

Resources

About